地诺单抗注射方法

(Xgeva) is a drug produced by the American company Amgen for the treatment of malignant tumors with bone metastasis. Which is most commonly used in our breast cancer patients with bone metastases. Denosumab is a transmembrane or soluble protein that plays an important role in the formation, function, and survival of osteoclasts and cells responsible for bone resorption, regulating the release of calcium from bone. Through RANKL stimulation, osteoclast activity is enhanced, mediating the occurrence of bone metastasis bone pathology in solid tumors. Denosumab can bind to the RANKL protein, preventing RANKL from binding to the receptor RANK expressed on the surface of osteoclasts, precursor cells, and osteoclast-like giant cells to activate subsequent malignant processes, thus exerting an anti-bone metastasis effect. Since many people are not particularly familiar with this drug, they do not dare to use it, and they are not very clear about the efficacy of denosumab. Let’s take a look at the injection methods and contraindications for denosumab.

The first thing we need to understand is the injection method and dosage of denosumab: (1) Give 120/mg by subcutaneous injection in the upper arm, upper thigh, or abdomen once every 4 weeks (2) Give calcium and vitamin D when it is necessary to treat or prevent hypocalcemia. The following are precautions: (1) Hypocalcemia, severe hypocalcemia, may occur in patients receiving Xgeva. Correct hypocalcemia before starting Xgeva. Monitor calcium levels and appropriately supplement all patients with calcium and vitamin D. (2) Osteonecrosis of the jaw may occur in patients receiving Xgeva. Have an oral examination before starting Xgeva. Monitor for symptoms. Avoid Invasive Dental Surgical Adverse Reactions During Treatment with Xgeva The most common adverse reactions (incidence greater than or equal to 25% of patients per case-patient) receiving Xgeva were fatigue/asthenia, hypophosphatemia, and nausea.

Finally, before we choose denosumab treatment, we need to understand whether we are a contraindication to this drug. (1) Pregnancy: According to animal data, it may cause fetal damage. Pregnancy monitoring programs available (2) Breastfeeding mothers: Breast development and lactation may be impaired. Discontinue drug or breastfeed (3) Pediatric patients: Placebo and effectiveness have not been established (4) Renal impairment: Patients with creatinine clearance less than 30 mL/min or receiving dialysis are at risk for hypocalcemia. If you are one of the above contraindications, it is best to discuss with your doctor about changing other anti-cancer drugs for treatment.